Among the key inflammatory processes is the formation of multiprotein complexes called inflammasomes. Inflammasomes are part of the innate immune system and play a vital role in recruiting immune cells to sites of infection and inflammation. Dysregulated inflammasome activation may promote processes that give rise to autoinflammatory, autoimmune, oncologic, metabolic and chronic diseases. Among the inflammasomes, NLRP3 is the most studied and has gained attention from both academic researchers and pharmaceutical companies.
Aqilion has identified a novel pharmacological strategy for selectively modulating NLRP3 inflammasome signaling. The internal Polaris project has the potential to be first in its class with this novel mechanism of action, thus providing a clear differentiation in a highly competitive field.